Intrinsic Imaging provides imaging core lab services in support of oncology clinical trials. Our oncology radiologists pair standardized tumor response assessment with advanced quantitative imaging, allowing sponsors to evaluate safety and efficacy in oncology and immuno-oncology with confidence. Having participated in hundreds of Phase I through IV oncology clinical trials, Intrinsic Imaging brings experience that spans a broad spectrum of cancer indications, imaging modalities, therapeutic mechanisms and study designs.
At Intrinsic Imaging, our Oncology Imaging division brings together more than 180 board-certified radiologists focused in oncology, with clinical trial imaging experience across solid tumors and hematologic malignancies. Our readers assess tumor response using established and emerging oncology criteria, including RECIST 1.1, iRECIST, mRECIST, Lugano, Cheson, RANO, PERCIST, Choi, PCWG-2, BI-RADS, and other indication- and protocol-specific methodologies.
Intrinsic Imaging supports oncology imaging endpoints across CT, MRI, PET/CT, SPECT, bone scintigraphy, and ultrasound, including diffusion, perfusion, volumetric, and quantitative PET methods. Our teams work closely with sponsors from protocol and imaging charter development through regulatory-ready data delivery to qualify imaging sites, standardize acquisition, maintain image quality control, conduct blinded independent central review (BICR) with adjudication, and perform quantitative analysis.
By combining subspecialty readers, consistently applied response criteria, and centralized quality control, Intrinsic Imaging helps sponsors protect the integrity of critical oncology endpoints and make confident clinical and regulatory decisions. This quality-controlled core lab infrastructure is backed by three FDA inspections with zero Form 483 observations and five ISO certifications.